A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 701–800 of 1,003
An Enzyme‐Directed Imidazoquinoline for Cancer Immunotherapy
Hantho, J. D., Strayer, T. A., Nielsen, A. E., & Mancini, R. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600443 · Cited by 23
de Goeje, P. L., Klaver, Y., Kaijen-Lambers, M. E. H., Langerak, A. W., Vroman, H. H., Kunert, A., Lamers, C. H. J., Aerts, J. G. J. V., Debets, R., & Hendriks, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02034 · Cited by 22
Bhojnagarwala, P. S., Perales‐Puchalt, A., Cooch, N. S., Sardesai, N. Y., & Weiner, D. B. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.005 · Cited by 22
Borden, E. S., Ghafoor, S., Buetow, K. H., LaFleur, B., Wilson, M. A., & Hastings, K. T. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100700 · Cited by 22
Modulation of T cell function and survival by the tumor microenvironment
Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22
Nguyen, K. B., Roerden, M., Copeland, C., Backlund, C. M., Klop-Packel, N. G., Remba, T. K., Kim, B., Singh, N. K., Birnbaum, M. E., Irvine, D. J., et al. (2023) · eLife · doi:10.7554/elife.85263 · Cited by 22
Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines
Sotirov, S., & Dimitrov, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094934 · Cited by 22
Birrueta, G., Frazier, A., Pomés, A., Glesner, J., Filep, S. C., Schal, C., Jeong, K. Y., McMurtrey, C., Schans, T. V., Hildebrand, W. H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00313 · Cited by 22
Self-citationA Self‐Assembled ATP Probe for Melanoma Cell Imaging
Cheng, H., Sun, Z., Kwon, N., Wang, R., Cui, Y., Park, C. O., & Yoon, J. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201806182 · Cited by 22
Neoantimon: a multifunctional R package for identification of tumor-specific neoantigens
Hasegawa, T., Hayashi, S., Shimizu, E., Mizuno, S., Niida, A., Yamaguchi, R., Miyano, S., Nakagawa, H., & Imoto, S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa616 · Cited by 22
Choueiri, T. K., Albiges, L. K., Atkins, M. B., Bakouny, Z., Bratslavsky, G., Braun, D. A., Haas, N. B., Haanen, J. B. A. G., Hakimi, A. A., Jewett, M. A. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3238 · Cited by 22
Bellmann, L., Strandt, H., Zelle‐Rieser, C., Ortner, D., Tripp, C. H., Schmid, S., Rühl, J., Cappellano, G., Schaffenrath, S., Prokopi, N., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149670 · Cited by 22
Exosome application in tumorigenesis: diagnosis and treatment of melanoma
Fath, M. K., Azargoonjahromi, A., Jafari, N., Mehdi, M., Alavi, F., Daraei, M., Mohammadkhani, N., Mueller, A., Brockmueller, A., Shakibaei, M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-021-01621-8 · Cited by 22
A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity
Xu, S., Wang, X. H., & Fei, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888556 · Cited by 22
Next Steps for Immunotherapy in Glioblastoma
Cao, T., Wainwright, D. A., Lee-Chang, C., Miska, J. M., Sonabend, A. M., Heimberger, A. B., & Lukas, R. V. (2022) · Cancers · doi:10.3390/cancers14164023 · Cited by 22
Prediction of cancer neoepitopes needs new rules
Brennick, C. A., George, M. M., Srivastava, P. K., & Karandikar, S. H. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101387 · Cited by 22
The Evolving Clinical Landscape for Dendritic Cell Vaccines and Cancer Immunotherapy
Cannon, M. J., Block, M. S., Morehead, L. C., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0129 · Cited by 22
Xia, Q.-H., Lu, C., Tong, M., Yue, M., Chen, R., Zhuge, D., Yao, Q., Xu, H., & Zhao, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648708 · Cited by 21
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
Zhang, X., Xu, Z. Q., Dai, X., Zhang, X., & Wang, X. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104860 · Cited by 21
Ge, W., Song, S., Qi, X., Chen, F., Che, X., Sun, Y., Wang, J., Li, X., Liu, N., Wang, Q., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.027942 · Cited by 21
Neoadjuvant personalized cancer vaccines: the final frontier?
Richard, G., Ruggiero, N., Steinberg, G. D., Martin, W. D., & Groot, A. S. D. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2303015 · Cited by 21
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Aparicio, B., Theunissen, P., Hervás‐Stubbs, S., Fortes, P., & Sarobe, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2303799 · Cited by 21
Current Strategies to Enhance Anti-Tumour Immunity
Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 21
Cancer research in the era of immunogenomics
Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 21
Koşaloğlu‐Yalçın, Z., Blazeska, N., Carter, H. K., Nielsen, M., Cohen, E. E. W., Kufe, D. W., Conejo-Garcia, J. R., Robbins, P. F., Schoenberger, S. P., Peters, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.735609 · Cited by 21
Virus‐Mimic mRNA Vaccine for Cancer Treatment
Meng, C., Chen, Z., Mai, J., Shi, Q., Tian, S., Hinkle, L. E., Li, J., Zhang, Z., Ramirez, M., Zhang, L., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100144 · Cited by 21
Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung
Taucher, E., Taucher, V., Fink‐Neuboeck, N., Lindenmann, J., & Smolle‐Jüttner, F. (2021) · Cancers · doi:10.3390/cancers13235972 · Cited by 21
Cancer Immunotherapy Beyond Checkpoint Blockade
Welty, N. E., & Gill, S. I. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.006 · Cited by 21
Immunotherapy for Lung Malignancies
Chee, J., Robinson, B. W. S., Holt, R. A., & Creaney, J. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.007 · Cited by 21
Targeting Autophagy in ALK-Associated Cancers
Frentzel, J., Sorrentino, D., & Giuriato, S. (2017) · Cancers · doi:10.3390/cancers9120161 · Cited by 21
PD-L1 Expression Affects Neoantigen Presentation
Okada, M., Shimizu, K., Iyoda, T., Ueda, S., Shinga, J., Mochizuki, Y., Watanabe, T., Ohara, O., & Fujii, S. (2020) · iScience · doi:10.1016/j.isci.2020.101238 · Cited by 21
DeepNovoV2: Better de novo peptide sequencing with deep learningPreprint
Qiao, R., Tran, N. H., Xin, L., Shan, B., Li, M., & Ghodsi, A. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1904.08514 · Cited by 21
Dotse, E., Lim, K. H., Wang, M., Wijanarko, K. J., & Chow, K. T. (2022) · Life · doi:10.3390/life12020323 · Cited by 20
Pandey, K., Wang, S. S., Mifsud, N. A., Faridi, P., Davenport, A. J., Webb, A. I., Sandow, J. J., Ayala, R., Monje, M., Cross, R. S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1192448 · Cited by 21
Faghfuri, E. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0054 · Cited by 20
Srivastava, P. K. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176740 · Cited by 20
S-Sulfenylation Driven Antigen Capture Boosted by Radiation for Enhanced Cancer Immunotherapy
Zhu, J., Li, M., Zhang, Y., Lv, Z., Zhao, Z., Guo, Y., Chen, Y., Ren, X., Cheng, X., & Shi, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c02206 · Cited by 20
Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment
Aggeletopoulou, I., Pantzios, S., & Triantos, C. K. (2025) · Cancers · doi:10.3390/cancers17030376 · Cited by 20
Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy
Wilson, E., & Anderson, K. S. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1545578 · Cited by 20
Ye, L., Ma, S., Robinson, B. W. S., & Creaney, J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1563488 · Cited by 20
Distinct genomic features across cytolytic subgroups in skin melanoma
Roufas, C., Georgakopoulos‐Soares, I., & Zaravinos, A. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02918-3 · Cited by 20
Polymeric Nanosystems for Immunogenic Cell Death‐Based Cancer Immunotherapy
Fu, L., Zhou, X., & He, C. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100075 · Cited by 20
Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
Zachariah, N. N., Basu, A. B., Gautam, N., Ramamoorthi, G., Kodumudi, K. N., Kumar, N. B., Loftus, L., & Czerniecki, B. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786286 · Cited by 20
Castro, A., Zanetti, M., & Carter, H. K. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-092820-112713 · Cited by 20
Autologous Melanoma Cell Vaccine Using Monocyte-Derived Dendritic Cells (NBS20/eltrapuldencel-T)
Javed, A., Sato, S., & Sato, T. (2016) · Future Oncology · doi:10.2217/fon.16.13 · Cited by 20
Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma
Johanns, T. M., & Dunn, G. P. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000247 · Cited by 20
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Ma, S., Chee, J., Fear, V. S., Forbes, C. A., Boon, L., Dick, I. M., Robinson, B. W. S., & Creaney, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1684714 · Cited by 20
Carretero-Iglesia, L., Couturaud, B., Baumgaertner, P., Schmidt, J., Hajjami, H. M.-E., Speiser, D. E., Hebeisen, M., & Rufer, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03016 · Cited by 20
Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment
Katsnelson, A. (2016) · Nature Medicine · doi:10.1038/nm0216-122 · Cited by 20
Liu, T., Yang, L. M., Hou, Y., Tian, Y., Ashrafizadeh, M., Orive, G., Han, M., & Yang, Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03695-2 · Cited by 19
The promises and challenges of neoantigen cancer vaccines
Ott, P. A. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03018-2 · Cited by 19
Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
Biri‐Kovács, B., Bánóczi, Z., Tummalapally, A., & Szabó, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020452 · Cited by 19
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
D’Alise, A. M., & Scarselli, E. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000923 · Cited by 19
Li, X., Zhu, G., Li, Y., Huang, H., Wu, D., 曹佩军, Shi, R., Chen, C., Su, L., Zhang, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1096818 · Cited by 19
Integrating immunopeptidome analysis for the design and development of cancer vaccines
Feola, S., Chiaro, J., & Cerullo, V. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101750 · Cited by 19
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties
Upadhye, A., Landeros, K. E. M., Ramírez-Suástegui, C., Schmiedel, B. J., Woo, E. B. C., Chee, S., Malicki, D. M., Coufal, N. G., Gonda, D. D., Levy, M. L., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00706-9 · Cited by 20
Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans
Fritsch, E. F., & Ott, P. A. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0565 · Cited by 19
Advancements in Melanoma Therapies: From Surgery to Immunotherapy
Shajari, N., Baradaran, B., Tohidkia, M. R., Nasiri, H., Sepehri, M., Setayesh, S., & Maleki, L. A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01239-8 · Cited by 19
Ye, Z., Li, Z., Jin, H., & Qian, Q. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_3 · Cited by 19
Cavalcante, L. L., Chowdhary, A., Sosman, J. A., & Chandra, S. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0359-4 · Cited by 19
Melssen, M. M., Olson, W. C., Wages, N. A., Capaldo, B. J., Mauldin, I. S., Mahmutovic, A., Hutchison, C., Melief, C. J. M., Bullock, T. N. J., Engelhard, V. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490855 · Cited by 20
Erdmann, M., Uslu, U., Wiesinger, M., Brüning, M., Altmann, T., Strasser, E. F., Schuler, G., & Schuler‐Thurner, B. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.09.012 · Cited by 19
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., López-Beltrán, A., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 19
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 19
What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
Redwood, A., Dick, I. M., Creaney, J., & Robinson, B. W. S. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2038403 · Cited by 19
Maruoka, S., Ojima, T., Iwamoto, H., Kitadani, J., Tabata, H., Tominaga, S., Katsuda, M., Hayata, K., Takeuchi, A., & Yamaue, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-07305-1 · Cited by 19
Zhou, S., Liu, S., Zhao, L., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.786438 · Cited by 19
Servín-Blanco, R., Chávaro-Ortiz, R. M., Zamora-Alvarado, R., Martínez‐Cortés, F., Gevorkian, G., & Manoutcharian, K. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.10.008 · Cited by 19
Dillman, R. O., Cornforth, A. N., McClay, E. F., & DePriest, C. B. (2019) · Melanoma Management · doi:10.2217/mmt-2018-0010 · Cited by 19
Low, S., & Nakamura, Y. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz073 · Cited by 19
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting
Penter, L., & Wu, C. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129209 · Cited by 19
Geometric deep learning improves generalizability of MHC-bound peptide predictions
(2024) · doi:10.1038/s42003-024-07292-1 · Cited by 18
Liao, W., Zhou, X., Lin, H., Feng, Z., Chen, X., Chen, Y., Chen, M., Lin, M., YAO, G., Chen, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557461 · Cited by 18
In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity
Chikovani, T., & Magen, E. (2025) · Vaccines · doi:10.3390/vaccines13111114 · Cited by 19
Personalized Cancer Vaccines: Current Advances and Emerging Horizons
Lu, L., Lu, X., & Luo, W. (2025) · Vaccines · doi:10.3390/vaccines13121231 · Cited by 18
Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity
Hernandez, R., & Malek, T. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878377 · Cited by 18
Carri, I., Schwab, E., Podaza, E., Alvarez, H. M. G., Mordoh, J., Nielsen, M., & Barrio, M. M. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00091 · Cited by 18
Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity
Bouma, R. G., Twilhaar, M. K. N., Brink, H. J., Affandi, A. J., Mesquita, B. S., Olesek, K., van Dommelen, J. M. A., Heukers, R., de Haas, A. M., Kalay, H., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124254 · Cited by 18
Peng, T., Shao, X., Song, W., Xu, W., Xiong, W., He, Y., Ding, Y., & Huang, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.08.042 · Cited by 18
Prospect and progress of personalized peptide vaccinations for advanced cancers
Sakamoto, S., Noguchi, M., Yamada, A., Itoh, K., & Sasada, T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1161752 · Cited by 18
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., Curran, M. A., Albershardt, T. C., Bajaj, A., Archer, J. F., Reeves, R. S., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0173-6 · Cited by 18
Frey, B. F., Jiang, J., Sui, Y., Boyd, L. F., Yu, B., Tatsuno, G. P., Billeskov, R., Solaymani-Mohammadi, S., Berman, P. W., Margulies, D. H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701523 · Cited by 18
Want, M. Y., Konstorum, A., Huang, R., Jain, V., Matsueda, S., Tsuji, T., Lugade, A. A., Odunsi, K. O., Koya, R. C., & Battaglia, S. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1586042 · Cited by 18
Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse
Rijensky, N. M., Blondheim-Shraga, N., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N. B.-C., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001876 · Cited by 18
Swartz, A. M., Congdon, K. L., Nair, S. K., Li, Q.-J., Herndon, J. E., Suryadevara, C. M., Riccione, K. A., Archer, G. E., Norberg, P. K., Sanchez-Perez, L. A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-020-00273-5 · Cited by 18
Self-adjuvanting photosensitizer nanoparticles for combination photodynamic immunotherapy
Zhang, G., Wang, N., Sun, H., Fu, X., Zhai, S., & Cui, J. (2021) · Biomaterials Science · doi:10.1039/d1bm01139a · Cited by 18
The role of proteomics in the age of immunotherapies
Hayes, S. A., Clarke, S. J., Pavlakis, N., & Howell, V. M. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9763-6 · Cited by 18
Aris, M., Bravo, A., Pampena, M. B., Blanco, P. A., Carri, I., Koile, D., Yankilevich, P., Levy, E. M., Barrio, M. M., & Mordoh, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00955 · Cited by 18
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Chiffelle, J., Genolet, R., Michielin, O. A., & Harari, A. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101076 · Cited by 17
Rähni, A., Jaago, M., Sadam, H., Pupina, N., Pihlak, A., Tuvikene, J., Annuk, M., Mägi, A., Timmusk, T., Ghaemmaghami, A. M., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00114-7 · Cited by 17
Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy
Ren, Y., Yue, Y., Li, X., Weng, S., Xu, H., Liu, L., Cheng, Q., Luo, P., Zhang, T., Liu, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113147 · Cited by 17
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 17
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects
Li, X., Zhu, Y., Xue, Y., Chen, T., Sun, X., & Shi, H. (2025) · Cancers · doi:10.3390/cancers17121953 · Cited by 18
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
Baxevanis, C. N., Fortis, S. P., Ardavanis, A. S., & Perez, S. A. (2020) · Cancers · doi:10.3390/cancers12102908 · Cited by 17
ProTECT—Prediction of T-Cell Epitopes for Cancer Therapy
Rao, A. A., Madejska, A. A., Pfeil, J., Paten, B., Salama, S. R., & Haussler, D. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.483296 · Cited by 17
Immunotherapies targeting neoantigens are effective in PD ‐1 blockade‐resistant tumors
Sun, C., Nagaoka, K., Kobayashi, Y., Maejima, K., Nakagawa, H., Nakajima, J., & Kakimi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.34382 · Cited by 17
Towards a better cancer precision medicine: Systems biology meets immunotherapy
Bhinder, B., & Elemento, O. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.01.006 · Cited by 17
Novel tumour antigens and the development of optimal vaccine design
Brentville, V. A., Atabani, S., Cook, K., & Durrant, L. G. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518768769 · Cited by 17
Macfarlane, F. R., Chaplain, M. A. J., & Lorenzi, T. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.07.019 · Cited by 17
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.